Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Johnson & Johnson (JNJ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 370,739,776
  • Shares Outstanding, K 2,686,520
  • Annual Sales, $ 71,890 M
  • Annual Income, $ 16,540 M
  • 36-Month Beta 0.82
  • Price/Sales 5.19
  • Price/Cash Flow 16.78
  • Price/Book 5.04

Price Performance

See More
Period Period Low Period High Performance
1-Month
137.89 +0.08%
on 11/17/17
144.35 -4.40%
on 10/23/17
-2.79 (-1.98%)
since 10/17/17
3-Month
129.05 +6.94%
on 09/29/17
144.35 -4.40%
on 10/23/17
+4.96 (+3.73%)
since 08/17/17
52-Week
109.32 +26.23%
on 12/07/16
144.35 -4.40%
on 10/23/17
+21.43 (+18.38%)
since 11/17/16

Most Recent Stories

More News
Glaxo's Triple Therapy COPD Inhaler Gets Marketing Nod in EU

Glaxo (GSK) and partner Innoviva announced that their triple combination therapy, Trelegy Ellipta, was granted marketing authorization in the EU as maintenance therapy for the treatment of patients with...

TBPH : 29.89 (+3.50%)
INVA : 13.06 (+0.69%)
JNJ : 138.00 (-0.63%)
GSK : 35.06 (-0.37%)
US Anticoagulation Therapy Market to 2022 - Major Players are C. H. Boehringer Sohn, Bristol-Myers Squibb, Johnson & Johnson, Pfizer, Daiichi Sankyo and Portola Pharmaceuticals

The "US Anticoagulation Therapy Market - Forecast to 2022" report has been added to Research and Markets' offering.

JNJ : 138.00 (-0.63%)
PTLA : 49.28 (+0.26%)
BMY : 61.32 (-0.89%)
Hip Replacement Lawsuit News: DePuy Pinnacle Plaintiffs Awarded $247 Million At Conclusion of 4th Federal Bellwether Trial, Bernstein Liebhard LLP Reports

Johnson & Johnson and its DePuy Orthopaedics subsidiary have been ordered to pay $247 million to six plaintiffs who experienced the premature failure of a metal-on-metal version of the companies' Pinnacle...

JNJ : 138.00 (-0.63%)
Federal Jury Returns $247 Million Verdict in Defective Hip Implants Case

A federal court jury in Texas returned a $247 million verdict on behalf of six people who suffered serious medical complications caused by the defective metal-on-metal hip implants made by Johnson & Johnson...

JNJ : 138.00 (-0.63%)
AstraZeneca's Faslodex Gets FDA Nod for Use With Verzenio

AstraZeneca's (AZN) drug Faslodex received FDA approval for a new indication.

AZN : 33.46 (-0.18%)
JNJ : 138.00 (-0.63%)
LLY : 82.89 (-0.66%)
PFE : 35.37 (-0.53%)
Pharma Stock Roundup: FDA Nod for AstraZeneca Severe Asthma Drug, Bayer Signs Deal with Loxo

Key highlights this week include the FDA approval of AstraZeneca's (AZN) severe asthma drug and Bayer's collaboration with Loxo for cancer.

BAYRY : 31.7900 (-0.05%)
AZN : 33.46 (-0.18%)
JNJ : 138.00 (-0.63%)
MRK : 55.20 (+0.05%)
LLY : 82.89 (-0.66%)
PCRX : 40.25 (+1.90%)
BMY : 61.32 (-0.89%)
Achillion Announces Pricing of Secondary Offering Of Common Stock

Achillion Pharmaceuticals, Inc. ("Achillion") (NASDAQ:ACHN) today announced the pricing of an underwritten public offering of 18,367,346 shares of its common stock by existing stockholder Johnson & Johnson...

ACHN : 3.43 (-3.65%)
JNJ : 138.00 (-0.63%)
MacroGenics Names Dr. Jay Siegel to its Board of Directors

MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well...

MGNX : 19.20 (+5.61%)
JNJ : 138.00 (-0.63%)
J&J Presents Positive New Data for Diabetes Drug Invokana

Johnson & Johnson (JNJ) puts forth positive data from CANVAS study on its type II diabetes drug, Invokana, showing better renal outcomes.

NVO : 50.91 (+0.81%)
JNJ : 138.00 (-0.63%)
MRK : 55.20 (+0.05%)
LLY : 82.89 (-0.66%)
Achillion (ACHN) Shares Down as J&J Announces Stake Sale

Achillion's (ACHN) shares fell following the announcement that J&J will sell its complete stake in the company.

SCMP : 10.55 (+1.93%)
ACHN : 3.43 (-3.65%)
JNJ : 138.00 (-0.63%)
ALXN : 110.87 (+0.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin...

See More

Key Turning Points

2nd Resistance Point 139.22
1st Resistance Point 138.61
Last Price 138.00
1st Support Level 137.64
2nd Support Level 137.28

See More

52-Week High 144.35
Last Price 138.00
Fibonacci 61.8% 130.97
Fibonacci 50% 126.84
Fibonacci 38.2% 122.70
52-Week Low 109.32

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart